L. reuteri NCIMB 30242: A Probiotic with Benefits

Abstract

Objectives: The objective of this study was to evaluate the effects of probiotic bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 on cholesterol lowering, mechanism of action and gastrointestinal (GI) symptomatology in hypercholesterolemic adults. Methods: 127 subjects consumed either L. reuteri NCIMB 30242 or placebo capsules over a 9-week intervention period in a randomized controlled trial. Results: L. reuteri NCIMB 30242 capsules reduced LDL-cholesterol by 11.6% (P=0.001), total cholesterol by 9.1%, (P<0.001), non-HDL-cholesterol by 11.3% (P<0.001), apoB-100 by 8.4% (P=0.002) and cholesteryl ester saturated fatty acids by 8.8% (P=0.002) relative to placebo over the intervention period. Treated subjects showed a significant increase in plasma deconjugated bile acids (P<0.05), indicating increased intraluminal deconjugation, and a significant decrease in plasma plant sterols (P<0.05). hs-CRP was reduced by 1.05 mg/l (P=0.005) in treated subjects relative to placebo with changes positively correlated to interleukin-6 and tumor necrosis factor-α. Further, a higher proportion of treated subjects reported improved symptoms for diagnosis of irritable bowel syndrome and unspecified functional bowel disorders (P<0.05). Conclusions: L. reuteri NCIMB 30242 capsules should be considered as an adjunctive therapy for hypercholesterolemia and may be useful for promoting GI health.

Full text

8/2/2014 L. reuteri NCIMB 30242: A Probiotic with Benefits -- Jones et al. 27 (1): 1079.20 -- The FASEB Journal
http://www.fasebj.org /cgi/content/meeting_abstract/27/1_MeetingAbstracts/1079.20 1/2
(The FASEB Journal. 2013;27:1079.20)
© 2013 FASEB
1079.20
L. reuteri NCIMB 30242: A Probiotic with Benefits
Mi tch el l L. J ones1, Ch ri s to pher J Ma rt on i 3 a nd S aty a Praka s h2
1 McGill Univer sity, Montreal, QC, Canada
2 Biomedical Eng., McGill University, Montreal, QC, Canada
3 Micropharm a, Montreal, QC, Canada
Objectives: The objective of this study was to evaluate the effects of probiotic
bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 on cholesterol
lowering, mechanism of action and gastrointestinal (GI) symptomatology in
hypercholesterolemic adults.
Methods: 127 subjects consumed either L. reuteri NCIMB 30242 or placebo
capsules over a 9-week intervention period in a randomized controlled trial.
Results: L. reuteri NCIMB 30242 capsules reduced LDL-cholesterol by 11.6%
(P=0.001), total cholesterol by 9.1%, (P<0.001), non-HDL-c holesterol by 11.3%
(P<0.001), apoB-100 by 8.4% (P=0.002) and cholesteryl ester saturated fatty acids
by 8.8% (P=0.002) relative to placebo over the intervention period. Treated
subjects showed a signific ant increase in plasma deconjugated bile acids
(P<0.05), indicating increased intraluminal deconjugation, and a significant
decrease in plasma plant sterols (P<0.05). hs-CRP was reduced by 1.05 mg/l
(P=0.005) in treated subjects relative to placebo with changes positively
correlated to interleukin-6 and tumor necrosis factor-α. Further, a higher
proportion of treated subjects reported improved symptoms for diagnosis of
irritable bowel syndrome and unspecified functional bowel disorders (P<0.05).
Conclusions: L. reuteri NCIMB 30242 capsules should be considered as an
adjunctive therapy for hypercholesterolemia and may be useful for promoting GI
health.

8/2/2014 L. reuteri NCIMB 30242: A Probiotic with Benefits -- Jones et al. 27 (1): 1079.20 -- The FASEB Journal
http://www.fasebj.org /cgi/content/meeting_abstract/27/1_MeetingAbstracts/1079.20 2/2